Free Trial
NASDAQ:PTIX

Atrinsic Q1 2025 Earnings Report

Atrinsic logo
$0.77 -0.01 (-0.78%)
As of 10/2/2026 12:23 PM Eastern

Atrinsic EPS Results

Actual EPS
-$2.75
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Atrinsic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atrinsic Announcement Details

Quarter
Q1 2025
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Atrinsic's next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules.

Conference Call Resources

Atrinsic Earnings Headlines

Atrinsic (NASDAQ:PTIX) Stock Price Down 5.1% - Time to Sell?
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.tc pixel
Protagenic Therapeutics, Inc. (PTIX) - Yahoo Finance
Protagenic Therapeutics swaps warrants for shares
See More Atrinsic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atrinsic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atrinsic and other key companies, straight to your email.

About Atrinsic

Atrinsic (NASDAQ:PTIX), Inc. was an internet marketing and digital media company that developed and operated online consumer brands and provided performance-based marketing services. Its activities included customer acquisition, advertising, lead generation and the distribution of digital content and services through online channels.

The company underwent a strategic transformation and later changed its name to Protagenic Therapeutics, Inc. As part of that transition, its business focus shifted away from internet marketing toward biotechnology and the development of peptide-based therapeutics. The company’s later work has centered on treatments for stress-related and anxiety disorders.

Atrinsic’s historical operations primarily served consumers and advertisers through internet-based platforms. Publicly available information about its former leadership, geographic reach and detailed operating history is limited, so a more comprehensive description of those aspects cannot be provided reliably.

View Atrinsic Profile